Namida Lab

Namida Lab is a revenue-stage diagnostics company pioneering the use of tears as a biofluid for early cancer detection. Its core technology platform analyzes the proteomic and genomic content of tears to identify biomarkers associated with cancers, starting with breast cancer. The company has commercialized two initial products: Auria, an at-home breast cancer screening test, and Melody, a clinical diagnostic for providers. By focusing on a non-invasive, easily collectible fluid, Namida Lab aims to disrupt traditional screening paradigms and improve patient compliance and outcomes.

Proteomic and genomic analysis platform for detecting cancer biomarkers from human tears. Utilizes mass spectrometry and AI/ML for biomarker discovery and test interpretation.

Namida Lab competes in the liquid biopsy and early cancer detection market against major players like Grail (multi-cancer early detection via blood) and Guardant Health. Its primary differentiation is the use of tears, which promises easier collection but must prove analytical and clinical performance comparable or superior to established blood-based methods.